金河生物(002688) - 2020 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2020 was ¥433,027,256.62, representing a 12.58% increase compared to ¥384,630,239.08 in the same period last year[7]. - Net profit attributable to shareholders was ¥54,075,869.30, a 43.31% increase from ¥37,734,004.99 year-over-year[7]. - The net profit after deducting non-recurring gains and losses was ¥53,166,354.15, up 48.60% from ¥35,778,746.87 in the previous year[7]. - The basic earnings per share increased by 50.00% to ¥0.09 from ¥0.06 in the same period last year[7]. - The total comprehensive income attributable to shareholders increased by ¥24,370,153.68, a growth of 68.80%[18]. - Net profit for Q1 2020 reached CNY 59,453,809.43, compared to CNY 36,784,353.67 in the same period last year, reflecting a growth of approximately 61.5%[46]. - The company reported a total comprehensive income of CNY 66,181,077.77 for Q1 2020, compared to CNY 34,066,575.69 in the same period last year[47]. Assets and Liabilities - The total assets at the end of the reporting period were ¥3,511,630,838.99, a 5.00% increase from ¥3,344,278,815.41 at the end of the previous year[7]. - The company's equity attributable to shareholders reached CNY 1,738,850,223.89, up from CNY 1,678,925,673.71, representing an increase of about 3.6%[38]. - Total liabilities increased to CNY 1,638,440,828.65 from CNY 1,537,400,385.63, which is an increase of approximately 6.6%[37]. - The company's total liabilities increased to CNY 1,135,020,827.97 from CNY 942,889,537.47, indicating a rise of about 20.5%[45]. - Current assets reached CNY 1,395,517,616.82, up from CNY 1,240,717,688.82, indicating an increase of about 12.5%[35]. Cash Flow - The net cash flow from operating activities was ¥169,026.42, a significant decrease of 95.47% compared to ¥3,731,560.95 in the same period last year[7]. - Cash inflow from operating activities amounted to CNY 404,345,431.78, an increase from CNY 376,065,554.73, reflecting a growth of about 7.5%[53]. - Cash outflow from operating activities totaled CNY 404,176,405.36, compared to CNY 372,333,993.78 in the previous year, showing an increase of approximately 8.5%[54]. - The net cash flow from financing activities increased by ¥43,487,733.71, a growth of 64.59%, mainly due to increased bank borrowings for loan repayments[21]. - The company reported a net cash outflow from investing activities of CNY 31,963,446.17, compared to CNY 29,802,810.33 in the previous year, indicating a decline of about 7.2%[54]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 35,395[10]. - The company's retained earnings increased to CNY 552,987,945.89 from CNY 498,912,076.59, showing a growth of approximately 10.8%[38]. Government Support and Other Income - The company received government subsidies amounting to ¥1,130,958.33 during the reporting period[8]. - Other comprehensive income after tax increased by ¥9,445,046.32, a growth of 347.53%, primarily due to foreign exchange differences[17]. - Interest income rose by ¥649,301.29, an increase of 271.82%, mainly from a one-time interest income received by a subsidiary[15]. Operational Costs - Total operating costs for Q1 2020 were CNY 365,234,360.24, up from CNY 340,404,778.12 in the previous period, with operating costs specifically rising from CNY 218,739,868.46 to CNY 267,084,257.49[45]. - Research and development expenses decreased to CNY 14,920,829.51 from CNY 19,235,074.07, showing a reduction of approximately 22.4%[45].